Literature DB >> 10871825

1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS.

J Suhy1, W D Rooney, D E Goodkin, A A Capizzano, B J Soher, A A Maudsley, E Waubant, P B Andersson, M W Weiner.   

Abstract

OBJECTIVE: To compare brain metabolite levels in patients with primary progressive (PP) and relapsing remitting (RR) MS and controls. HYPOTHESES: (1) creatine (Cr), a putative marker of gliosis, is elevated and N-acetylaspartate (NAA), a putative marker of axonal density and functional integrity, is reduced in PPMS lesions and normal appearing white matter (NAWM) compared to control white matter; (2) The pattern of metabolite change in PPMS is different than in RRMS.
METHODS: MRI and proton magnetic resonance spectroscopic imaging (1H MRSI) were collected from 15 PPMS patients, 13 RRMS patients, and 20 controls.
RESULTS: Cr was increased in PPMS NAWM compared to controls (P=0.035), and compared to RRMS NAWM (P=0.038). Cr was increased in focal MRI lesions from PPMS compared to lesions from RRMS (P=0.044) and compared to control white matter (P=0.041). NAA was similarly reduced in PPMS and RRMS NAWM compared to control. NAA was similarly reduced in PPMS and RRMS lesions, compared to control white matter.
CONCLUSIONS: Creatine is higher in PPMS than RRMS NAWM and focal lesions. This observation is consistent with the notion that progressive disability in PPMS reflects increased gliosis and axonal loss whereas disability in RRMS reflects the cumulative effects of acute inflammatory lesions and axonal loss.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10871825      PMCID: PMC2733351          DOI: 10.1177/135245850000600303

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  37 in total

1.  A comparison of the pathology of primary and secondary progressive multiple sclerosis.

Authors:  T Revesz; D Kidd; A J Thompson; R O Barnard; W I McDonald
Journal:  Brain       Date:  1994-08       Impact factor: 13.501

2.  Reduced phase encoding in spectroscopic imaging.

Authors:  A A Maudsley; G B Matson; J W Hugg; M W Weiner
Journal:  Magn Reson Med       Date:  1994-06       Impact factor: 4.668

3.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.

Authors:  F D Lublin; S C Reingold
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

4.  Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy.

Authors:  P M Matthews; E Pioro; S Narayanan; N De Stefano; L Fu; G Francis; J Antel; C Wolfson; D L Arnold
Journal:  Brain       Date:  1996-06       Impact factor: 13.501

5.  The transverse magnetisation decay characteristics of longstanding lesions and normal-appearing white matter in multiple sclerosis.

Authors:  D Kidd; G J Barker; P S Tofts; A Gass; A J Thompson; W I McDonald; D H Miller
Journal:  J Neurol       Date:  1997-02       Impact factor: 4.849

6.  Brain metabolite changes in alcoholism: an in vivo proton magnetic resonance spectroscopy (MRS) study.

Authors:  N R Jagannathan; N G Desai; P Raghunathan
Journal:  Magn Reson Imaging       Date:  1996       Impact factor: 2.546

7.  Soluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive disease.

Authors:  G Giovannoni; J W Thorpe; D Kidd; B E Kendall; I F Moseley; A J Thompson; G Keir; D H Miller; M Feldmann; E J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-01       Impact factor: 10.154

8.  Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis.

Authors:  M Filippi; A Campi; V Martinelli; B Colombo; T Yousry; N Canal; G Scotti; G Comi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-11       Impact factor: 10.154

Review 9.  The natural history of multiple sclerosis.

Authors:  B G Weinshenker
Journal:  Neurol Clin       Date:  1995-02       Impact factor: 3.806

10.  Evaluation of multiple sclerosis by 1H spectroscopic imaging at 4.1 T.

Authors:  J W Pan; H P Hetherington; J T Vaughan; G Mitchell; G M Pohost; J N Whitaker
Journal:  Magn Reson Med       Date:  1996-07       Impact factor: 4.668

View more
  30 in total

Review 1.  Imaging of multiple sclerosis: role in neurotherapeutics.

Authors:  Rohit Bakshi; Alireza Minagar; Zeenat Jaisani; Jerry S Wolinsky
Journal:  NeuroRx       Date:  2005-04

Review 2.  The role of advanced magnetic resonance imaging techniques in primary progressive MS.

Authors:  Maria A Rocca; Martina Absinta; Massimo Filippi
Journal:  J Neurol       Date:  2011-08-04       Impact factor: 4.849

3.  Whole-brain N-acetylaspartate concentration: correlation with T2-weighted lesion volume and expanded disability status scale score in cases of relapsing-remitting multiple sclerosis.

Authors:  Fabrice Bonneville; David M Moriarty; Belinda S Y Li; James S Babb; Robert I Grossman; Oded Gonen
Journal:  AJNR Am J Neuroradiol       Date:  2002-03       Impact factor: 3.825

Review 4.  MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system.

Authors:  Massimo Filippi; Maria Assunta Rocca
Journal:  J Neurol       Date:  2005-11       Impact factor: 4.849

Review 5.  Utility of magnetic resonance spectroscopic imaging for human epilepsy.

Authors:  Jullie W Pan; Ruben I Kuzniecky
Journal:  Quant Imaging Med Surg       Date:  2015-04

6.  Interaction of loci within the HLA region influences multiple sclerosis course in the Sardinian population.

Authors:  M G Marrosu; E Cocco; G Costa; M R Murru; C Mancosu; R Murru; M Lai; C Sardu; P Contu
Journal:  J Neurol       Date:  2005-08-17       Impact factor: 4.849

7.  Robust outer volume suppression utilizing elliptical pulsed second order fields (ECLIPSE) for human brain proton MRSI.

Authors:  Chathura Kumaragamage; Henk M De Feyter; Peter Brown; Scott McIntyre; Terence W Nixon; Robin A de Graaf
Journal:  Magn Reson Med       Date:  2019-11-19       Impact factor: 4.668

Review 8.  Recent advances in the neuroimaging of multiple sclerosis.

Authors:  William D Rooney; Patricia K Coyle
Journal:  Curr Neurol Neurosci Rep       Date:  2005-05       Impact factor: 5.081

9.  Cerebral energetic effects of creatine supplementation in humans.

Authors:  J W Pan; K Takahashi
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2006-12-21       Impact factor: 3.619

10.  Statistical estimation of T1 relaxation times using conventional magnetic resonance imaging.

Authors:  Amanda F Mejia; Elizabeth M Sweeney; Blake Dewey; Govind Nair; Pascal Sati; Colin Shea; Daniel S Reich; Russell T Shinohara
Journal:  Neuroimage       Date:  2015-12-28       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.